Monday, September 29, 2025
Revvity, Inc. has announced the launch of its Living Image™ Synergy AI multimodal analysis software, a powerful new solution designed to transform how in vivo imaging researchers analyze and interpret data. The platform unifies imaging analysis across multiple modalities including optical, microCT, ultrasound, and others—to reduce inconsistencies, streamline workflows, and accelerate discovery. By integrating AI into the process, the software also enhances reproducibility, increases throughput, and provides researchers with greater confidence in their findings.
“Our Living Image Synergy AI software marks a significant leap forward in preclinical imaging analysis,” said Kevin Quick, VP of platforms at Revvity. “Tracking, monitoring, and visualizing biological processes and disease progression is central to understanding complex biology and evaluating potential therapeutics early in development. By unifying disparate analysis tools and integrating AI into existing workflows, Revvity’s new solution is directed towards enabling earlier insights and more consistent analysis across modalities, and greater reproducibility across studies ultimately helping researchers move faster and with more confidence.”
The Living Image Synergy AI software was created to eliminate the limitations researchers face when juggling separate imaging tools. Instead of relying on siloed systems, scientists can now correlate datasets seamlessly within a single, centralized platform. This unified approach enables them to uncover deeper biological insights that may otherwise remain hidden when working with disconnected technologies.
To further boost efficiency, the platform includes intuitive co-registration tools that align data from multiple imaging sources, making it easier to interpret results. Additionally, automated processes significantly reduce manual workloads and the time required for analysis. At the core of this innovation are AI-driven algorithms that automate critical tasks such as image segmentation and region-of-interest (ROI) quantification. These steps, once highly labor-intensive and prone to human variability, are now streamlined to deliver more consistent, accurate, and statistically reliable outcomes.
By combining automation with advanced analytics, Revvity’s software not only saves valuable research time but also strengthens reproducibility an essential factor in advancing preclinical studies and therapeutic development. Researchers can now monitor disease progression, evaluate drug efficacy, and explore complex biological processes with improved precision and scalability.
With the launch of Living Image Synergy AI, Revvity continues to demonstrate its commitment to equipping scientists with next-generation tools that accelerate innovation and drive breakthroughs in life sciences research.
Recommended News
To join our expert panel discussions, reach out to sudipto@intentamplify.com
Tags:
POET and Sivers partner to develop light source modules for AI data centers, boosting Co-Packaged Optics with strong financial backing and strategic collaboration.
Chinese company DeepSeek releases experimental AI model version DeepSeek-V3.2-Exp, marking a key step in advancing its AI technology development.
